JAMA by Engels, Eric A. et al.
Spectrum of Cancer Risk among U.S. Solid Organ Transplant
Recipients: The Transplant Cancer Match Study
Eric A. Engels,
National Cancer Institute, Rockville, MD
Ruth M. Pfeiffer,
National Cancer Institute, Rockville, MD
Joseph F. Fraumeni Jr.,
National Cancer Institute, Rockville, MD
Bertram L. Kasiske,
Scientific Registry of Transplant Recipients and Minneapolis Medical Research Foundation,
Minneapolis, MN
Ajay K. Israni,
Scientific Registry of Transplant Recipients and Minneapolis Medical Research Foundation,
Minneapolis, MN
Jon J. Snyder,
Scientific Registry of Transplant Recipients and Minneapolis Medical Research Foundation,
Minneapolis, MN
Robert A. Wolfe,
Scientific Registry of Transplant Recipients and Arbor Research Collaborative for Health, Ann
Arbor, MI
Nathan P. Goodrich,
Address correspondence to: Eric A. Engels, MD MPH, Infections and Immunoepidemiology Branch, Division of Cancer
Epidemiology and Genetics, National Cancer Institute, DHHS, 6120 Executive Blvd, EPS 7076, Rockville, MD 20892, USA, Phone:
301-496-8115, Fax: 301-402-0817, engelse@exchange.nih.gov.
Eric Engels takes responsibility for the whole content of this paper. Author contributions are as follows.
• Conception and design: Engels, Fant, Fraumeni, Lin, Pfeiffer, Wolfe
• Acquisition of data: Bayakly, Clarke, Copeland, Engels, Finch, Fleissner, Goodman, Goodrich, Israni, Kahn, Kasiske,
Koch, Lin, Lynch, Madeleine, Pawlish, Rao, Snyder, Williams, Wolfe
• Analysis and interpretation of data: all authors
• Drafting of the manuscript: Engels
• Critical revision of the manuscript for important intellectual content: Bayakly, Castenson, Clarke, Copeland, Curry, Fant,
Finch, Fleissner, Fraumeni, Goodman, Goodrich, Israni, Kahn, Kasiske, Koch, Lin, Lynch, Madeleine, Parsons, Pawlish,
Pfeiffer, Rao, Snyder, Williams, Wolfe
• Statistical analysis: Castenson, Curry, Engels, Goodrich, Parsons, Pfeiffer
• Supervision: Engels, Fant, Lin
• Obtaining funding, Engels, Fraumeni, Fant, Lin
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of
Interest. Bertram L. Kasiske reported that he receives grant funding from BMS. Ajay K. Israni reported that he receives grant funding
Bristol-Myers Squibb, Roche, and Genzyme. Jon J. Snyder reported that he receives consultancy fees and research support from
Genzyme, research support from Bristol-Myers Squibb, and payment for development of educational presentations from the American
Society of Nephrology. No other disclosures were reported.
NIH Public Access
Author Manuscript
JAMA. Author manuscript; available in PMC 2012 May 2.
Published in final edited form as:













Scientific Registry of Transplant Recipients and Arbor Research Collaborative for Health, Ann
Arbor, MI
A. Rana Bayakly,
Georgia Comprehensive Cancer Registry, Atlanta, GA
Christina A. Clarke,
Cancer Prevention Institute of California, Fremont, California
Glenn Copeland,
Michigan Department of Community Health, Lansing, MI
Jack L. Finch,
Colorado Central Cancer Registry, Denver, CO
Mary Lou Fleissner,
Connecticut Tumor Registry, Hartford, CT
Marc T. Goodman,
University of Hawaii, Honolulu, HI
Amy Kahn,
New York State Cancer Registry, Albany, NY
Lori Koch,
Illinois State Cancer Registry, Springfield, IL
Charles F. Lynch,
University of Iowa, Iowa City, IA
Margaret M. Madeleine,
Fred Hutchinson Cancer Research Center, Seattle, WA
Karen Pawlish,
New Jersey Department of Health and Senior Services, Trenton, NJ
Chandrika Rao,
North Carolina Central Cancer Registry, Raleigh, NC
Melanie A. Williams,
Texas Department of State Health Services, Austin, TX
David Castenson,
Information Management Services, Rockville, MD
Michael Curry,
Information Management Services, Rockville, MD
Ruth Parsons,
Information Management Services, Rockville, MD
Gregory Fant, and
Health Resources and Services Administration, Rockville, MD
Monica Lin
Health Resources and Services Administration, Rockville, MD
Abstract
Context—Solid organ transplant recipients have elevated cancer risk due to immunosuppression
and oncogenic viral infections. Since most prior research has concerned kidney recipients, large
studies that include recipients of differing organs can inform cancer etiology.
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Objective—Describe the overall pattern of cancer among solid organ transplant recipients.
Design—Cohort study using linked data from the U.S. Scientific Registry of Transplant
Recipients (1987–2008) and 13 state/regional cancer registries.
Participants and Setting—Solid organ transplant recipients in the U.S.
Main Outcome Measure—Standardized incidence ratios (SIRs) and excess absolute risks
(EARs) assessing relative and absolute cancer risk in transplant recipients compared to the general
population.
Results—Registry linkages yielded data on 175,732 solid organ transplants (58.4% kidney,
21.6% liver, 10.0% heart, 4.0% lung). Overall cancer risk was elevated (N=10,656 cases,
incidence 1374.7 per 100,000 person-years; SIR 2.10, 95%CI 2.06–2.14; EAR 719.3, 95%CI
693.3–745.6, per 100,000 person-years). Risk was increased (p<0.001) for 32 different
malignancies, some related to known infections (e.g., anal cancer, Kaposi sarcoma) and others
unrelated (e.g., melanoma, thyroid and lip cancers). The most common malignancies with elevated
risk were non-Hodgkin lymphoma (N=1504, incidence 194.0; SIR 7.54, 95%CI 7.17–7.93; EAR
168.3, 95%CI 158.6–178.4) and cancers of the lung (N=1344, incidence 173.4; SIR 1.97, 95%CI
1.86–2.08; EAR 85.3, 95%CI 76.2–94.8), liver (N=930, incidence 120.0; SIR 11.56, 95%CI
10.83–12.33; EAR 109.6, 95%CI 102.0–117.6), and kidney (N=752, incidence 97.0; SIR 4.65,
95%CI 4.32–4.99; EAR 76.1, 95%CI 69.3–83.3). Lung cancer risk was most elevated in lung
recipients (SIR 6.13, 95%CI 5.18–7.21) but also increased among other recipients (SIR 1.46,
95%CI 1.34–1.59 for kidney; 1.95, 1.74–2.19 for liver; 2.67, 2.40–2.95 for heart). Liver cancer
was elevated only among liver recipients (SIR 43.83, 95%CI 40.90–46.91), who manifested
exceptional risk in the first 6 months (SIR 508.97, 95%CI 474.16–545.66) and continuing two-
fold excess for 10–15 years (SIR 2.22, 95%CI 1.57–3.04). Among kidney recipients, kidney
cancer was elevated (SIR 6.66, 95%CI 6.12–7.23) and bimodal in onset. Kidney cancer was also
increased in liver and heart recipients (SIR 1.80, 95%CI 1.40–2.29, and 2.90, 2.32–3.59,
respectively).
Conclusions—Recipients of a kidney, liver, heart, or lung transplant have an increased risk for
diverse infection-related and unrelated cancers, compared with the general population.
Introduction
Solid organ transplantation provides life-saving therapy for patients with end-stage organ
disease. In 2010, a total of 28,664 transplants were performed in the U.S., including 16,899
kidney, 6291 liver, 2333 heart, and 1770 lung transplants (1). Although transplant outcomes
have improved dramatically over time, substantial morbidity results from chronic
immunosuppressive therapy administered to prevent graft rejection.
Cancer is a major adverse outcome of solid organ transplantation (2). Previous studies have
demonstrated an overall 2–4-fold elevated risk of cancer (3–11). Excess risk is largely due to
immunosuppression, with a spectrum of cancer resembling that seen with human
immunodeficiency virus (HIV) infection, another immunosuppressing condition (11). Risks
are especially high for malignancies caused by viral infections, including non-Hodgkin
lymphoma (NHL) and Hodgkin lymphoma (both due to Epstein Barr virus [EBV]), Kaposi
sarcoma (human herpesvirus 8), anogenital cancers (human papillomavirus), and liver
cancer (hepatitis C and B viruses). Certain other malignancies, such as cancers of the lung,
kidney, skin, and thyroid, are also increased in transplant recipients.
Linkage of population-based transplant and cancer registries from the same geographic
region can allow for systematic ascertainment of cancer outcomes in a large representative
population of recipients. Except for a recent study from the United Kingdom with 37,616
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transplant recipients (4), prior linkage studies of cancer following transplantation included
2000–11,000 recipients (3;5–9), which is not large enough to accurately estimate risk for
less common cancers. Also, these previous studies have mostly been limited to kidney
recipients. As a result, it is unclear how cancer risk varies according to the transplanted
organ.
A better understanding of cancer risk in transplant recipients would help clarify the role of
the immune system, infections, and other factors in the development of malignancy, and
could identify opportunities to improve transplant safety. To this end, we conducted the
Transplant Cancer Match Study, a linkage of the U.S. solid organ transplant registry with
state and regional cancer registries. We herein present an initial overview of cancer risk in
recipients of all organ types, based on data for more than 175,000 transplant recipients. In
addition, we provide further details for the four most common malignancies for which risk is
elevated in transplant recipients and which together comprise over 40% of all cases.
Methods
Overview of the U.S. transplant registry and linkage with cancer registries
The 1984 National Organ Transplant Act established the U.S. Organ Procurement and
Transplantation Network (OPTN). Transplant programs are required to be OPTN members
to perform solid organ transplantation in the U.S. The OPTN collects information from
transplant centers and organ procurement organizations regarding transplant candidates,
recipients, and donors. At 6 months after transplant and at yearly intervals, transplant centers
provide follow-up data on recipients’ vital status and graft function. These data are provided
monthly by the OPTN to the Scientific Registry of Transplant Recipients (SRTR,
http://www.srtr.org). The SRTR thus includes data on all U.S. solid organ transplant
recipients since 1987, including demographic characteristics, medical indication for
transplant, and characteristics of transplanted organs. Additional vital status information is
obtained through linkage with the U.S. Social Security Death Master File.
During December 2008 through June 2010, we linked the SRTR with 13 U.S. population-
based cancer registries, covering the states of California (years of complete cancer data:
1988–2008), Colorado (1988–2006), Connecticut (1973–2006), Georgia (1995–2008),
Hawaii (1973–2007), Illinois (1986–2007), Iowa (1973–2007), Michigan (1985–2006), New
Jersey (1979–2006), New York (1976–2007), North Carolina (1990–2007), and Texas
(1995–2006), and the Seattle-Puget Sound area of Washington state (1974–2008). Database
linkages between the SRTR and cancer registries were accomplished using a computer-
based probabilistic matching algorithm followed by a manual review of potential matches.
Variables incorporated in the match included name, sex, date of birth, and social security
number.
Following each linkage, investigators retained information regarding cancer cases that
matched to SRTR transplant recipients. The study was approved by human subjects
committees at the National Cancer Institute and the following cancer registries: California,
Colorado, Connecticut, Georgia, Hawaii, Illinois, Iowa, Michigan, New Jersey, New York,
Seattle-Puget Sound, and Texas. It was reviewed and exempted from human subjects
approval at the Health Resources and Services Administration and the North Carolina cancer
registry.
Statistical analyses
As of June 2010, the SRTR included 458,834 U.S. solid organ transplants. Of these, 442,629
were during 1987–2008, a period for which cancer registries in our study provided data on
incident cancers. We evaluated cancer risk among the cohort of transplant recipients who
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resided in the geographic areas covered by the cancer registries and who were followed
during the periods when cancer ascertainment was considered at least 95% complete.
Residence of transplant recipients was determined based on the location recorded in the
SRTR at the time of transplant (32.1%) or listing as a candidate (61.4%); 6.6% had missing
information and were excluded. Thus, through linkages with the 13 population-based cancer
registries, and after exclusions based on geographic and temporal coverage, data on cancer
risk were available for 176,974 transplants (40.0% of 442,629 transplants). Finally, we
restricted analysis to individuals of the major race/ethnicity groups (non-Hispanic white,
non-Hispanic black, Hispanic, and Asian/Pacific Islander) to allow comparison with general
population cancer rates. Exclusion of persons of race/ethnicity outside the major categories
(N=1242 transplants) yielded the final cohort of 175,732 transplants.
For each area, transplant recipients were considered at risk of cancer beginning at
transplantation or start of cancer registry coverage (whichever came last). Follow-up ended
at death, failure of a transplanted organ, a subsequent transplant, loss to follow-up, or last
date of cancer registry coverage (whichever came first). Individuals were not censored when
they developed a first cancer and could develop multiple cancers of different types. The unit
of analysis was the transplant, and individuals were considered at risk separately during
successive transplant episodes. The overall transplant cohort was constructed by combining
data from each registry area.
Invasive cancers were classified using the Surveillance, Epidemiology, and End Results
(SEER) program “site recode with Kaposi sarcoma and mesothelioma”
(http://seer.cancer.gov/), except that we separately considered cancers of poorly specified
histology (because these could represent undiagnosed cases of post-transplant
lymphoproliferative disorder) and collapsed some rare categories. Based on a recent review
by the International Agency for Research on Cancer (12), we considered the following
malignancies to be related to infections: non-Hodgkin lymphoma, Hodgkin lymphoma, and
nasopharyngeal cancer (due to Epstein Barr virus); cancers of the cervix, vulva, vagina,
penis, anus, and oropharynx including tonsil (human papillomavirus); liver cancer (hepatitis
B and C viruses); Kaposi sarcoma (human herpesvirus 8); and stomach (Helicobacter
pylori). In geographic areas outside the U.S., biliary tract and bladder cancers are linked to
parasites, but these were considered unrelated to infections for our analyses. For purposes of
presentation, other cancers were considered unrelated to infections, although evidence of
variable strength supports links to infections for some additional subtypes (e.g., Merkel cell
polyomavirus for Merkel cell carcinoma of the skin).
Observed cancers in the transplant cohort were determined through the linkage with the
cancer registry. These observed counts were compared with the expected number, calculated
by applying general population cancer rates to person-time at risk among transplant
recipients. Specifically, person-time in the cohort was stratified by sex, age, race/ethnicity,
calendar year, and cancer registry area. We then applied general population cancer rates for
each stratum to the corresponding increment of person-time and summed the resulting
products for each person, yielding expected counts for the overall cohort or subgroups of
interest. We used strata of single calendar years and evaluated age in five-year intervals (0–
4, 5–9, …, 80–84, 85+ years). For each cancer registry area, general population cancer rates
for whites, blacks, and Asians/Pacific Islanders were calculated using the cancer registry’s
case counts and U.S. census population estimates. For Hispanics, we used cancer rates from
SEER to calculate expected counts. Because SEER data on Hispanics were available only
beginning in 1992, we restricted analysis for Hispanic transplant recipients to those years.
For Kaposi sarcoma, we used SEER rates from 1973–1979 to calculate expected counts for
all recipients, because general population rates of Kaposi sarcoma since 1980 have been
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strongly influenced by the HIV epidemic (13). We present observed and expected incidence
rates based on these case counts and the total follow-up time in the cohort.
To measure relative risk of cancer in transplant recipients compared to the general
population, we calculated a standardized incidence ratio (SIR) for each cancer type (i.e.,
observed/expected cases). We also calculated excess absolute risk (EAR = observed
incidence minus expected incidence) to measure absolute cancer risk attributable to
transplant. Ninety-five percent confidence intervals (CIs) for the SIR and EAR were derived
using an exact method that assumes that the observed counts follow a Poisson distribution
(14). We focus on SIRs with an exact p-value less than 0.001 (Bonferroni correction for
multiple comparisons, based on approximately 50 cancer types).
We performed additional analyses for the four most common cancers for which SIRs were
significantly elevated (NHL, and cancers of the lung, liver, and kidney). For these cancers,
we compared incidence across strata defined by sex, age, and transplanted organ (kidney,
liver, heart, or lung). We used univariate Poisson regression models to test for heterogeneity
in incidence across these strata. We also present SIRs based on these strata. We also
calculated SIRs in eight successive time intervals (1–180, 181–360, 361–720, 721–1080,
1081–1440, 1441–1800, 1801–3600, and 3601–5400 days after transplant [i.e.,
approximately 0.01–0.50, 0.51–1.00, 1.01–2.00, 2.01–3.00, 3.01–4.00, 4.01–5.00, 5.01–
10.00, and 10.01–15.00 years after transplant]), for the overall cohort and subgroups defined
by transplanted organ.
Results
Overview of transplant recipients and cancer risk
We evaluated cancer risk in a cohort of 175,732 transplants (39.7% of the U.S. total during
1987–2008). Recipients included in the study were similar to those excluded (Table 1),
except that included recipients were limited to four major racial/ethnic groups (and had a
larger fraction of Hispanics and Asians/Pacific Islanders) and were more likely to be
transplanted during 1995–2004. Most included recipients were male (60.90%), and the
median age at transplant was 47 years. The most common transplanted organs were kidney
(58.42%), liver (21.56%), heart (10.01%), and lung (3.99%).
Transplant recipients were linked to 10,656 malignancy diagnoses during follow-up,
corresponding to an overall doubling of cancer risk compared with the general population
(SIR 2.10, 95%CI 2.06–2.14). Overall cancer incidence in transplant recipients was 1375 per
100,000 person-years, corresponding to an EAR of 719.3 (95%CI 693.3–745.6) per 100,000
person-years.
As shown in Table 2, SIRs were significantly elevated (p<0.001) for most infection-related
malignancies, including NHL, Kaposi sarcoma, Hodgkin lymphoma, and cancers of the
liver, stomach, oropharynx, anus, vulva, and penis. Risks of cervical, nasopharyngeal, and
vaginal cancers were not significantly increased. Among infection-unrelated malignancies,
SIRs were significantly elevated (p<0.001) for cancers of the lung, kidney, colorectum,
thyroid, urinary bladder, other oral cavity and pharynx sites, skin (non-melanoma, non-
epithelial), pancreas, lip, esophagus, larynx, soft tissue, salivary gland, small intestine, testis,
intrahepatic bile duct and other biliary sites, and eye/orbit, and for melanoma, plasma cell
neoplasms, acute myeloid leukemia, and chronic myeloid leukemia. In contrast, risk was
decreased for breast cancer and, to a lesser extent, prostate cancer.
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Additional analyses for NHL and cancers of the lung, liver, and kidney
We conducted additional analyses for the four most common malignancies with elevated
risk: NHL (N=1504, incidence 194.0; SIR 7.54, 95%CI 7.17–7.93; EAR 168.3, 95%CI
158.6–178.4), and cancers of the lung (N=1344, incidence 173.4; SIR 1.97,95%CI 1.86–
2.08; EAR 85.3, 95%CI 76.2–94.8), liver (N=930, incidence 120.0; SIR 11.56, 95%CI
10.83–12.33; EAR 109.6, 95%CI 102.0–117.6), and kidney (N=752, incidence 97.0; SIR
4.65, 95%CI 4.32–4.99; EAR 76.1, 95%CI 69.3–83.3).
Among transplant recipients, incidence of these four cancers was higher in males than
females and increased steeply with age (Table 3). NHL was an exception to this pattern:
both younger and older recipients (age 0–34 or 50+ years at transplant) had higher incidence
than middle-aged recipients (age 35–49 years). SIRs for NHL, liver cancer, and kidney
cancer were especially elevated for the youngest recipients, reflecting large increases
relative to the general population.
As shown in Table 3, NHL incidence was highest in lung recipients, intermediate in liver
and heart recipients, and lowest in kidney recipients. For the other three malignancies,
incidence was greatest in recipients of the corresponding organ (Table 3). This difference by
transplanted organ was most pronounced for liver cancer, with 89.4% of cases arising in
liver recipients.
For NHL, risk was elevated for both nodal and extranodal lymphomas (SIR 6.08, 95%CI
5.68–6.51, and 10.72, 9.93–11.56, respectively; Table 2). As shown in Table 3, the elevation
in NHL risk was greatest among lung recipients (SIR 18.73, 95%CI 15.59–22.32), but
substantial elevations were also seen for other recipients (SIR 6.05, 95%CI 5.59–6.54 for
kidney; 7.77, 6.99–8.61 for liver; 7.79, 6.89–8.79 for lung). Among all recipients together
and for each organ separately, NHL risk was highest in the first year after transplant, then
fell, and increased again to a plateau beginning at 4–5 years after transplant (Figure 1).
For lung cancer, the elevated risk was greatest among lung recipients (SIR 6.13, 95%CI
5.18–7.21) but was also present for recipients of other organs (SIR 1.46, 95%CI 1.34–1.59
for kidney; 1.95, 1.74–2.19 for liver; 2.67, 2.40–2.95 for heart). Among transplant recipients
overall, lung cancer risk increased gradually over time, but the pattern varied by transplanted
organ (Figure 2). Risk for lung recipients was especially high in the first 6 months after
transplant (SIR 11.17, 95%CI 7.48–16.04) and persisted at a lower level throughout follow-
up (Figure 2). Excluding the first 6 months, lung cancer risk was elevated 5.5-fold in lung
recipients compared with the general population (SIR 5.53, 95%CI 4.58–6.63). As shown in
Figure 2, recipients of other organs had smaller elevations in risk that were somewhat
constant (kidney and liver recipients) or gradually increasing over time (heart recipients).
For liver cancer, liver recipients had a strongly elevated risk compared to the general
population (SIR 43.83, 95%CI 40.90–46.91). Among liver recipients, 95.4% of liver cancers
were diagnosed in the first 6 months after transplant, leading to remarkable risk during this
interval (SIR 508.97, 95%CI 474.16–545.66). Nonetheless, liver cancer risk remained
elevated among liver recipients throughout subsequent follow-up, albeit at a much lower
level (SIR 2.22, 95%CI 1.57–3.04, excluding the first 6 months after transplantation; Figure
3). Among recipients of other organs, liver cancer risk showed no elevation (Table 3, Figure
3).
Kidney cancer risk was highest in kidney recipients (SIR 6.66, 95%CI 6.12–7.23), but was
also elevated among liver and heart recipients (SIRs 1.80, 95%CI 1.40–2.29, and 2.90, 2.32–
3.59, respectively). Among all recipients, kidney cancer risk showed a bimodal pattern over
time (Figure 4). The early peak was largely due to the high risk during the first year among
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kidney recipients (SIRs 7.28–10.28), and a second peak in risk was seen during years 4–15
after kidney transplant. Patterns over time were similar for liver and heart recipients,
although SIRs were lower (Figure 4).
Discussion
In this large population-based study of U.S. transplant recipients, we observed a two-fold
overall increased risk of cancer, corresponding to an excess absolute risk attributable to
transplantation of approximately 0.7% per year. The spectrum of cancer risk was broad,
including numerous infection-related and unrelated malignancies. NHL and cancers
corresponding to three commonly transplanted organs (kidney, liver, and lung) together
comprised 43% of all cancer cases in recipients, compared with 21% in the U.S. general
population (15).
Elevated risks were seen for NHL and a variety of other malignancies associated with
persistent viral infections. These increases resemble the cancer risks associated with HIV
infection (11) and appear related to poor immune control of known oncogenic viruses. The
absence of increased risk for cervical cancer (caused by human papillomavirus) may reflect
Pap smear screening of recipients and prompt treatment of precancerous lesions (16).
Although we did not see an elevated risk of nasopharyngeal cancer (linked to EBV), our
study included relatively few Asians, who may be uniquely predisposed (17). Risk was
elevated for gastric cancer, caused by the bacterium Helicobacter pylori.
Risk was also increased for certain malignancies without established links to infections. A
few (e.g., melanoma, plasma cell neoplasms including multiple myeloma and
plasmacytomas) are increased in HIV-infected populations (11) and may reflect loss of
immune surveillance or the effects of chronic inflammation or immune activation. Some
may be caused by yet unknown infections. Notably, transplant recipients appear prone to
several cancers (e.g., colorectum, thyroid, and lip) that are not increased or occur much less
often with HIV infection (11). The elevated risk of bladder cancer among transplant
recipients (but not HIV-infected individuals) may be related to underlying medical
conditions leading to transplantation (e.g., analgesic nephropathy) (18;19).
NHL was the most common malignancy in U.S. transplant recipients. Among transplant
recipients, NHL represents one extreme of EBV-driven proliferative disease (termed “post-
transplant lymphoproliferative disorder”, PTLD), which ranges from benign hyperplasia and
infectious mononucleosis to lymphoid malignancy (20). The most common NHL subtype
among both transplant recipients and HIV-infected individuals is diffuse large B-cell
lymphoma, and most cases are EBV-positive (20;21). Bimodal onset of NHL and PTLD
following organ transplantation (Figure 1) has been described previously (21;22), and risk
factors differ somewhat for early-onset and late-onset PTLD, supporting etiologic
heterogeneity (23). NHL risk was most pronounced among young transplant recipients, who
are susceptible to primary EBV infection following transplantation (23–25). As reported
previously (26), NHL risk was especially high among lung recipients, possibly as a result of
the intensity of immunosuppression or the large amount of lymphoid tissue conveyed within
the lung graft.
Lung cancer risk was most elevated among lung recipients, perhaps due to smoking-related
lung diseases (e.g., chronic obstructive pulmonary disease) that may be the indication for
lung transplant. Among lung recipients, the majority of whom receive single-lung
transplants, most lung cancers arise in the remaining native lung (27;28). However, some
cancers observed in the first 6 months may reflect delayed reports of cancers discovered in
the explanted lung (29;30). Discounting these early cancers, lung cancer risk increased over
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time among lung recipients (Figure 2), suggesting a cumulative effect of transplantation. We
found lower, but still elevated, risks of lung cancer among kidney and liver recipients.
Unfortunately, the SRTR does not include data on tobacco use. The elevated risk of lung
cancer among HIV-infected people, independent of tobacco use, suggests that chronic
immunosuppression, pulmonary inflammation, or repeated lung infections contribute to
development of this malignancy (31).
Elevated risk of liver cancer was observed only among liver recipients. The extraordinary
risk in the first six months after liver transplant is probably an artifact of delayed recognition
or reporting of liver cancer. Liver cancer is a common complication of end-stage liver
disease (32), and liver transplantation is an accepted therapy for localized liver cancer (33).
We therefore suspect that the vast majority of early cancers were prevalent cases from the
explanted liver. After excluding these early cancers, we still observed a two-fold increase in
liver cancer among liver recipients followed for up to 15 years. Some late-onset liver
cancers may represent recurrent disease or new cases related to diabetes mellitus or infection
with hepatitis C or B virus (particularly common among liver recipients) (34).
The elevated risk of kidney cancer among kidney recipients is well described (3–5;7–11).
Some early cases arise as a result of malignant transformation of cysts that develop in end-
stage kidneys prior to transplantation (35;36). However, the elevated risk of late-onset
kidney cancers, including those arising in non-kidney recipients, is not readily explained.
The recent U.K. study also found an elevated risk of kidney cancer among non-kidney
recipients (4). It is possible that nephrotoxic or directly carcinogenic effects of some
immunosuppressive medications may contribute to cancers arising in the donor kidney (in
kidney recipients) or the relatively normal kidneys in other recipients (37;38). In
comparison, the absence of an increased risk of kidney cancer in HIV-infected people is
striking and argues against a major role for chronic immunosuppression (19).
Strengths of the Transplant Cancer Match Study include its large size and (despite minor
differences from the excluded recipients) representative sampling of the U.S. transplant
population. Inclusion of non-kidney recipients allowed comparison of cancer risk across
transplanted organs. Our study was more than four times larger than the recent U.K. study
(4), which allowed us to stratify our analyses of cancer risk over time according to the
transplanted organ. Also, the large sample size allowed stable estimates of risk for rare
cancers, which were not presented by Collett et al. (4).
While the present overview provides an overall picture of cancer risk, a limitation is that we
could not present detailed analyses for individual cancers. Future analyses will focus on
specific cancers that occur excessively and examine associations with medical conditions
and individual immunosuppressive medications. We identified malignancies through linkage
with population-based cancer registries, which assured largely complete ascertainment.
However, because cancer data were not available for the entire U.S., we would have missed
cancers if recipients moved away from their state or region after their transplant. SRTR
follow-up data regarding recipients’ residence are largely missing before 2003, but due to
changes in data collection policies, these data are more than 95% complete for subsequent
years. Based on addresses for the subset followed in 2003–2008, we estimate that the
proportion of transplant recipients who were not residing in their initial state or region was
2.3% at 6 months, 2.9% at 1 year, 3.9% at 3 years, 4.6% at 5 years, and 5.8% at 10 years.
Because this outmigration would have led to proportionate decreases in ascertainment of
cancer, these results indicate that our cancer risk estimates were not greatly affected even
after extended follow-up after transplant.
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We note that patterns of cancer risk in transplant recipients may partly reflect artifacts of
cancer screening. For example, decreased breast and prostate cancer risk may arise from
screening before transplant, leading to removal of prevalent cancers or deferral of transplant
in candidates with cancer. Additionally, transplant recipients may appear to have elevated
risk for some cancers (e.g., melanoma, kidney and thyroid cancers) because of heightened
medical surveillance (39). Finally, we could not evaluate squamous cell and basal cell skin
cancers, because these tumors are not collected by cancer registries.
In conclusion, this large-scale registry linkage study documents a wide spectrum of cancer
risk among transplant recipients. Some malignancies arise from the loss of immunologic
control of oncogenic viruses, but others are unrelated to known infections. Additional
contributing factors for some cancers may include other effects of chronic immune
disturbance or inflammation, underlying medical conditions, or medication toxicity. Our
findings should stimulate research into carcinogenic mechanisms associated with organ
transplantation. The elevated risk for a broad range of malignancies among transplant
recipients, coupled with improvements in long-term survival, should encourage further
development of approaches to prevention and early detection of cancer targeted to this
population.
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Risk of non-Hodgkin lymphoma following transplantation. Standardized incidence ratios
and associated 95% confidence intervals are shown according to time since transplantation
and transplanted organ. The vertical axis shows the standardized incidence ratios on a log-
scale. Results are presented for all transplants (solid circle), kidney transplants (open
square), liver transplants (open circle), heart transplants (open triangle), and lung transplants
(open diamond). The number of observed cancer events is shown below the figure;
corresponding expected counts are presented in eTable 1.
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Risk of lung cancer following transplantation. Standardized incidence ratios and associated
95% confidence intervals are shown according to time since transplantation and transplanted
organ. The vertical axis shows the standardized incidence ratios on a log-scale. Results are
presented for all transplants (solid circle), kidney transplants (open square), liver transplants
(open circle), heart transplants (open triangle), and lung transplants (open diamond). The
number of observed cancer events is shown below the figure; corresponding expected counts
are presented in eTable 1.
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Risk of liver cancer following transplantation. Standardized incidence ratios and associated
95% confidence intervals are shown according to time since transplantation and transplanted
organ. The vertical axis shows the standardized incidence ratios on a log-scale. Results are
presented for all transplants (solid circle), kidney transplants (open square), liver transplants
(open circle), heart transplants (open triangle), and lung transplants (open diamond). The
number of observed cancer events is shown below the figure; corresponding expected counts
are presented in eTable 1. Standardized incidence ratios are off-scale and therefore not
presented for 0.01–0.50 years after transplantation, for all transplants combined
(standardized incidence ratio 126.11, 95%CI 117.69–134.98) and for liver transplants
(standardized incidence ratio 508.97, 95%CI 474.16–545.66). For some other estimates, the
standardized incidence ratio was zero and so cannot be shown on the log-scale. When the
standardized incidence ratio was zero, the upper confidence limit is displayed, with the
exception of the estimate for lung transplants at 10.01–15.00 years after transplant, for
which the upper limit is also off-scale (95% upper confidence interval 49.64).
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Risk of kidney cancer following transplantation. Standardized incidence ratios and
associated 95% confidence intervals are shown according to time since transplantation and
transplanted organ. The vertical axis shows the standardized incidence ratios on a log-scale.
Results are presented for all transplants (solid circle), kidney transplants (open square), liver
transplants (open circle), heart transplants (open triangle), and lung transplants (open
diamond). The number of observed cancer events is shown below the figure; corresponding
expected counts are presented in eTable 1. For some estimates, the standardized incidence
ratio was zero and so cannot be shown on the log-scale. When the standardized incidence
ratio was zero, the upper confidence limit is displayed, with the exception of the estimate for
lung transplants at 10.01–15.00 years after transplant, for which the upper limit is also off-
scale (95% upper confidence interval 32.73).
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Table 1







Total 175,732 (100.00) 266,897 (100.00)
Sex
  Male 107,027 (60.90) 164,473 (61.62)
  Female 68,705 (39.10) 102,424 (38.38)
Age at transplant, years
  0–17 13,813 (7.86) 19,265 (7.22)
  18–34 29,444 (16.76) 45,443 (17.03)
  35–49 55,837 (31.77) 85,973 (32.21)
  50–64 62,815 (35.74) 95,705 (35.86)
  65+ 13,823 (7.87) 20,511 (7.68)
Race/ethnicity
  White, non-Hispanic 106,895 (60.83) 189,289 (70.92)
  Black, non-Hispanic 29,928 (17.03) 48,827 (18.29)
  Hispanic 28,263 (16.08) 18,429 (6.90)
  Asian/Pacific Islander 10,646 (6.06) 6,026 (2.26)
  Other/unknown 0 (0.00) 4,326 (1.62)
Transplanted organ
  Kidney 102,654 (58.42) 161,002 (60.32)
  Kidney and pancreas 6,165 (3.51) 9,607 (3.60)
  Pancreas 1,639 (0.93) 3,631 (1.36)
  Liver 37,888 (21.56) 50,894 (19.07)
  Heart 17,593 (10.01) 26,860 (10.06)
  Lung 7,013 (3.99) 10,900 (4.08)
  Heart and lung 388 (0.22) 563 (0.21)
  Other or multiple 2,392 (1.36) 3,440 (1.29)
Transplant number
  First 160,383 (91.27) 242,691 (90.93)
  Second 14,079 (8.01) 21,863 (8.19)
  Third or higher 1,270 (0.72) 2,343 (0.88)
Calendar year of transplant
  1987–1994 34,583 (19.68) 74,943 (28.08)
  1995–1999 46,110 (26.24) 55,041 (20.62)
  2000–2004 56,888 (32.37) 65,202 (24.43)
  2005–2008 38,151 (21.71) 71,711 (26.87)
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